Q3 2023 Results - Reimagining Medicine slide image

Q3 2023 Results - Reimagining Medicine

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology Oncology Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 66 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation